Drug Trial Radar · NCT06694389
Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age
Last checked: Nov 19, 2026Latest source record: Dec 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,457
Actual
Start
Nov 18, 2024
Primary completion
Nov 17, 2025
Study completion Nov 17, 2025
Sponsor
- Lead sponsor
- ModernaTX, Inc.Moderna (MRNA)
- Sponsor type
- Industry
- First posted
- Nov 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the immunogenicity, reactogenicity, and safety of mRNA-1083 in adults 50 years of age and older in participating countries (Japan, Taiwan, and South Korea).
Conditions
- COVID-19
- Influenza
Interventions
mRNA-1083Biological
Suspension for injection
PlaceboOther
0.9% sodium chloride suspension for injection
Licensed Influenza VaccineBiological
Aqueous injectable (SC) or suspension for injection (IM)
SARS-CoV-2 VaccineBiological
Suspension for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Geometric Mean (GM) Level of Antibodies for Influenza, as Measured by Hemagglutination Inhibition (HAI) AssayTime frame: Day 29
- GM Level of Antibodies for SARS-CoV-2, as Measured by Pseudovirus Neutralization Assay (PsVNA)Time frame: Day 29
- Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)Time frame: Day 1 through 7 days after study injection
- Number of Participants With Unsolicited Adverse Events (AEs)Time frame: Day 1 through 28 days after study injection
- Number of Participants With Medically Attended Adverse Events (MAAEs)Time frame: Day 1 though Day 181
- Number of Participants With Adverse Events of Special Interest (AESIs)Time frame: Day 1 though Day 181
- Number of Participants With Serious Adverse Events (SAEs)Time frame: Day 1 through Day 181
- Number of Participants With AEs Leading to DiscontinuationTime frame: Day 1 through Day 181
Locations
44 sites in 3 countries. Site status is shown where the registry gives one.
Public Health Association.Inc.
Nagoya, Aichi-ken, Japan
Daido Clinic
Nagoya, Aichi-ken, Japan
Tenjin Sogo Clinic
Fukuoka, Fukuoka, Japan
PS Clinic - Internal medicine
Fukuoka, Fukuoka, Japan
Fukuoka Heartnet Hospital
Fukuoka, Fukuoka, Japan
Medical Coporation of Yamazaki Neurotology, Rhinolaryngology Clinical
Sapporo, Hokkaido, Japan
Motomachi Takatsuka Naika Clinic - Internal Medicine
Yokohama, Kanagawa, Japan
Sakurajyuji Medical Corporation Medimesse Sakurajyuji Clinic
Kumamoto, Kumamoto, Japan
Nishi-Kumamoto Hospital
Kumamoto, Kumamoto, Japan
Sato Hospital
Osaki-shi, Miyagi, Japan
Yokoi Medicine Clinic
Mino, Osaka, Japan
Shinwakai Adachi Kyosai Hospital - Internal Medicine
Adachi-ku, Tokyo, Japan
Dojinkinenkai Meiwa Hospital
Chiyoda-ku, Tokyo, Japan
Nihonbashi Sakura Clinic
Chuo-ku, Tokyo, Japan
Tokyo center clinic - Internal medicine
Chuo-ku, Tokyo, Japan
Medical Corporation Asbo Tokyo Asbo Clinic
Chuo-ku, Tokyo, Japan
New Medical Research System Clinic
Hachioji-shi, Tokyo, Japan
Shimamura Memorial Hospital
Nerima City, Tokyo, Japan
Denenchofu Family Clinic
Ōta-ku, Tokyo, Japan
Hillside Clinic Jingumae
Shibuya-ku, Tokyo, Japan
Clinical Research Tokyo Hospital - Clinical Research Center
Shinjuku, Tokyo, Japan
Higashi-Shinjuku Clinic - Internal Medicine
Shinjuku, Tokyo, Japan
Shinei Medical Healthcare Clinic
Suginami, Tokyo, Japan
Souseikai Sumida Hospital
Sumida-Ku, Tokyo, Japan
Seishukai Clinic
Taito-ku, Tokyo, Japan
Metropolitan Clinic - Internal Medicine
Toshima-ku, Tokyo, Japan
Korea University Ansan Hospital
Ansan-si, South Korea
Kyungpook National University Hospital - Infectious Diseases
Daegu, South Korea
Chonnam National University Hospital - Allergology
Gwangju, South Korea
Inha University Hospital
Incheon, South Korea
Seoul National University Bundang Hospital
Seongnam-si, South Korea
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Hallym University Kangnam Sacred Heart Hospital
Seoul, South Korea
Korea University Guro Hospital
Seoul, South Korea
Ajou University Hospital
Suwon, South Korea
Yonsei University, Wonju Severance Christian Hospital
Wŏnju, South Korea
Kaohsiung Medical University - Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
Kaohsiung Veterans General Hospital
Kaohsiung City, Taiwan
Kuang Tien General Hospital - Dajia
Taichung, Taiwan
National Cheng Kung University Hospital
Tainan, Taiwan
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.